Accelerating Rare disease Cures Program
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- Points of contact
-
- CDER Acquisition Liaison cderacquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is forecasting a new requirement for the Accelerating Rare Disease Cures Program, which will procure scientific and technical consulting services to support the FDA's Office of New Drugs (OND) in advancing rare disease treatment development. The contract will leverage both Budget Authority (BA) and Prescription Drug User Fee Act (PDUFA) funding to facilitate the acceleration of cure development for rare diseases. The solicitation is estimated to be released on August 1, 2025, with an anticipated award date of January 1, 2026.
The contract award value is estimated between $700,000 and $1,500,000, classified under NAICS code 541690 (Other Scientific and Technical Consulting Services). This procurement does not include a small business set-aside. Interested vendors should direct inquiries to the FDA's acquisition liaison at cderacquisitions@fda.hhs.gov for additional information regarding this forecasted opportunity.
Forecast text
Rare Disease Funding - BA and PDUFA for OND's Advancing Rare Disease Cures Program
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast